Profile
BLPH NVO REGN VRTX MRNA SGEN
Company Name Bellerophon Therapeutics, Inc. Novo Nordisk A/S Regeneron Pharmaceuticals, Inc. Vertex Pharmaceuticals Incorporated Moderna, Inc. Seagen Inc.
Sector Healthcare Healthcare Healthcare Healthcare Healthcare Healthcare
Industry Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology Biotechnology
Market Cap $764.54K $566.57B $103.71B $103.60B $47.86B $43.15B
Employees 0.02K 66.02K 13.68K 5.40K 5.60K 3.26K
CEO Mr. Craig R. Jalbert CIRA Mr. Lars Fruergaard Jorgensen Dr. Leonard S. Schleifer M.D., Ph.D. Dr. Reshma Kewalramani FASN, M.D. Mr. Stephane Bancel Mr. David R. Epstein B.Sc., M.B.A.
Ratings
BLPH NVO REGN VRTX MRNA SGEN
Quant Rating Score 2 5 5 5 2 3
Quant Rating Sell Strong Buy Strong Buy Strong Buy Sell Neutral
Trading
BLPH NVO REGN VRTX MRNA SGEN
Last Close $0.0625 $123.05 $957 $401.08 $125 $228.74
High 52 $10.52 $199.54 $993.35 $446.08 $137.75 $228.9
Low 52 $0.03 $87.78 $692.45 $323.57 $69.51 $187.64
Price vs. 52 Week High -99.41 % -38.33 % -3.66 % -10.09 % -9.26 % -0.07 %
Price vs. 52 Week Low 108.33 % 40.18 % 38.2 % 23.95 % 79.83 % 21.9 %
Total Return
BLPH NVO REGN VRTX MRNA SGEN
1 Month Return 13.64 % -2.23 % 1.52 % -1.37 % 21.5 % 0 %
3 Month Return -2.34 % 4.05 % 2.21 % -6.48 % 30.9 % 0 %
6 Month Return 60.26 % 25.34 % 17.15 % 6.61 % 61.23 % 6.39 %
9 Month Return -86.35 % -21.42 % 24.86 % 17.8 % 15.54 % 18.23 %
YTD Return 68.92 % 18.95 % 8.96 % -1.43 % 25.69 % 0 %
1 Year Return -99.31 % -24.62 % 25.57 % 15.22 % -8.79 % 14.44 %
3 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
5 Year Return 0 % 0 % 0 % 0 % 0 % 0 %
Dividends
BLPH NVO REGN VRTX MRNA SGEN
Dividend Yield Percentage (TTM) - 0.16 % - - - -
Dividend Paid and Capex Coverage Ration (TTM) - 1.1 % 6.2 % 13.69 % -3.65 % -3.35 %
Dividend Per Share (TTM) - 0.2 % - - - -
Payout Ratio (TTM) - 47.03 % - - - -
Growth
BLPH NVO REGN VRTX MRNA SGEN
Asset Growth -70.47 % 30.35 % 13.23 % 25.23 % -28.74 % -1.21 %
Gross Profit Growth - 32.32 % 6.49 % 9.25 % -85.12 % 22.93 %
Revenue Growth - 31.26 % 7.76 % 10.17 % -64.94 % 24.65 %
Revenue 3 Year - 90.51 % 55.67 % 59.87 % 2356.27 % 91.84 %
Revenue 5 Year - 124.2 % 110.3 % 218.58 % 1070.62 % 215.48 %
Revenue 10 Year - 66.11 % 549.62 % 608.27 % 6447.35 % 494.04 %
EBIT Growth -11.03 % 37.11 % -14.6 % -12.94 % -145 % 10.13 %
Net Income Growth -11.69 % 50.71 % -8.87 % 8.96 % -156.37 % 9.51 %
Net Income 3 Yeari Growth Per Share 29.52 % 106.79 % 13.48 % 34.59 % -529.9 % -764.83 %
Net Income 5 Yeari Growth Per Share 90.16 % 133.86 % 74.02 % 70.33 % -160.17 % -276.93 %
Net Income 10 Yeari Growth Per Share 42.03 % 98.61 % 871.12 % 809.6 % -2046.03 % -624.16 %
Operating Income Growth -11.03 % 37.11 % -14.6 % -12.94 % -145 % 10.13 %
Operating Cash Flow Growth (CFG) 22.13 % 38.06 % -8.39 % -14.35 % -162.6 % 9.07 %
Operating 3 Year CFG 35.23 % 118.29 % 76.95 % 9.63 % -253.56 % -148.34 %
Operating 5 Year CFG 69.31 % 163.51 % 125.17 % 174.78 % -100.11 % -195.86 %
Operating 10 Year CFG 33.71 % 150.92 % 713.56 % 5187.08 % -4698.89 % -2622.09 %
EPS Growth -11.23 % 52.28 % -8.54 % 8.33 % -158.15 % 10.81 %
EPS Diluted Growth -11.23 % 52.37 % -9.03 % 8.35 % -161.39 % 10.81 %
Book Value Per Share -88.34 % 29 % 15.03 % 25.58 % -25.28 % -9.83 %
Share Holder 3 Year Equity Growth Per Share -66.73 % 75.22 % 137.56 % 104.06 % 439.94 % 33.92 %
Share Holder 5 Year Equity Growth Per Share 126.56 % 121.9 % 219.1 % 291.14 % 92.24 % 220.81 %
Share Holder 10 Year Equity Growth Per Share 130.8 % 49.62 % 1286.9 % 1030.79 % 1519.81 % 691.19 %
Dividend Per Share Growth - 26.89 % - - - -
Dividend 3 Year Growth Per Share - 64.4 % - - - -
Dividend 5 Year Growth Per Share - - - - - -
Dividend 10 Year Growth Per Share - 95.44 % - - - -
Debt Growth -78.74 % 4.74 % 0.06 % 44.1 % 3.58 % -23.28 %
Free Cash Flow Growth 22.13 % 9.17 % -17.11 % -16.47 % -183.5 % 3.67 %
Updated On 31 Dec 2022 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2023 31 Dec 2022
Profitability
BLPH NVO REGN VRTX MRNA SGEN
Gross Profit Margin TTM 100 % 84.65 % 87.16 % 87.21 % 21.77 % 75.4 %
Return on Assets TTM -234.38 % 29.87 % 11.22 % 15.92 % -35.67 % -20.64 %
Return on Equity TTM -207.63 % 91.82 % 15.15 % 22.62 % -41.83 % -28.06 %
Return on Capital Employed TTM -296.4 % 82.5 % 12.53 % 19.82 % -35.81 % -29.5 %
Net Income Per EBT TTM 110.83 % 79.81 % 95.44 % 82.64 % 124.28 % 101.53 %
EBT Per Ebit TTM 95.42 % 101.7 % 104.74 % 115.19 % 93.44 % 93.47 %
EBIT Per Revenue TTM -195.66 % 45.03 % 29.46 % 38.53 % -99.69 % -34.37 %
Cash Flow To Debt Ratio TTM - 346.88 % 238.94 % 437.57 % -232.98 % -475.96 %
Receivables Turnover TTM - 3.87 2.51 6.31 13.32 3.64
Payables Turnover TTM - 2.88 2.51 3.46 22.04 2.52
Inventory Turnover TTM - 1.12 0.62 1.71 13.67 1.07
Fixed Asset Turnover TTM - 248.64 % 310.02 % 679.28 % 186.78 % 471.71 %
Asset Turnover TTM 113.28 % 81.71 % 38.12 % 43.42 % 30.81 % 63.3 %
Operating Cash Flow Per Share TTM -1.01 20.95 43.96 13.73 -7.54 -2.87
Free Cash Flow Per Share TTM -1.01 11.28 36.87 12.72 -9.61 -3.73
Cash Per Share TTM 35.82 % 208.61 % 9758.35 % 4354.48 % 2235.6 % 657.5 %
Operating Cash Flow Sales Ratio TTM -218.78 % 38.24 % 36.17 % 35.84 % -55.91 % -23.48 %
Free Cash Flow Operating Cash Flow Ratio TTM 100 % 53.85 % 83.87 % 92.69 % 127.41 % 129.82 %
Cash Flow Coverage Ratios TTM - 346.88 % 238.94 % 437.57 % -232.98 % -475.96 %
Price To Free Cash Flows Ratio TTM -0.06 78.04 26.09 31.6 -13.03 -61.54
Price To Operating Cash Flows Ratio TTM -0.06 40.71 21.77 29.22 -16.57 -79.67
Price Cash Flow Ratio TTM -0.06 40.71 21.77 29.22 -16.57 -79.67
Income Statement (TTM)
BLPH NVO REGN VRTX MRNA SGEN
Revenue $0B $232.26B $13.12B $9.84B $6.75B $1.96B
Gross Profit $0B $196.5B $11.3B $8.58B $2.06B $1.55B
Gross Profit Ratio 0% 84.6% 86.16% 87.17% 30.52% 79.1%
EBITDA $-0.02B $112.94B $5.13B $3.93B $-3.21B $-0.62B
Net Income $-0.02B $83.68B $3.95B $3.62B $-4.71B $-0.61B
EPS Diluted -2.08 18.62 34.77 13.89 -12.34 -3.3
Balance Sheet (MRQ)
BLPH NVO REGN VRTX MRNA SGEN
Long Term Debt $0B $20.53B $2.7B $0.72B $1.22B $0.04B
Total Liabilities $0.01B $207.93B $7.11B $5.15B $4.57B $0.87B
Total Equity $0B $106.56B $25.97B $17.58B $13.85B $2.8B
Total Investments $0B $17.5B $13.51B $3.45B $4.68B $1.42B
Total Debt $0B $27.01B $2.7B $0.81B $1.24B $0.04B
Total Assets $0.01B $314.49B $33.08B $22.73B $18.43B $3.67B
Cash Flow Statement (TTM)
BLPH NVO REGN VRTX MRNA SGEN
Net Income $-0.02B $83.68B $3.95B $3.62B $-4.71B $-0.61B
Inventory $0B $-7.42B $-0.27B $-0.32B $0.75B $-0.23B
Dividends Paid $0B $-31.77B $0B $0B $0B $0B
Operating Cash Flow $-0.02B $108.91B $4.59B $3.54B $-3.12B $-0.45B
Capital Expenditure $0B $-38.9B $-0.93B $-0.26B $-0.71B $-0.08B
Related Stocks
Ticker Name Price
AADI Aadi Bioscience, Inc. 2.12
ABCL AbCellera Biologics Inc. 4.03
ABCM Abcam plc 23.99
ABEO Abeona Therapeutics Inc. 4.615
ABIO ARCA biopharma, Inc. 3.26
ABOS Acumen Pharmaceuticals, Inc. 3.49
ABSI Absci Corporation 5.08
ABUS Arbutus Biopharma Corporation 2.71
ABVC ABVC BioPharma, Inc. 1.08
ABVX Abivax SA American Depositary Shares 14.54
ACAD ACADIA Pharmaceuticals Inc. 17.05
ACER Acer Therapeutics Inc. 0.6601
ACET Adicet Bio, Inc. 1.45
ACGN Aceragen, Inc. 0.3849
ACHL Achilles Therapeutics plc 0.8037
ACHV Achieve Life Sciences, Inc. 4.735
ACIU AC Immune SA 2.39
ACLX Arcellx, Inc. 52.69
ACRV Acrivon Therapeutics, Inc. Common Stock 9.59
ACST Acasti Pharma Inc. 2.96
ETFs With Exposure to BLPH
Ticker ETF Name Weight Percentage Price
IWC iShares Micro-Cap ETF 0.0011 116.72
DFAT Dimensional U.S. Targeted Value ETF 0.00000009 52.49
DFAC Dimensional U.S. Core Equity 2 ETF 0.00000106 31.01
Unlock